Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2219-2231

  Bruce, E ^a   Shenoy, V ^a   Rathinasabapathy, A ^a   Espejo, A ^a   Horowitz, A ^a   Oswalt, A ^a   Francis, J ^b   Nair, A ^b   Unger, T ^c   Raizada, M K ^a   Steckelings, U M ^d   Sumners, C ^a   Katovich, M J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; COMPOUND 21; HORMONE RECEPTOR STIMULATING AGENT; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 7-ALA-ANGIOTENSIN (1-7); ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CARDIOVASCULAR AGENT; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; MONOCROTALINE; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOPULMONARY FIBROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SELECTIVITY; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; LUNG BLOOD VESSEL; LUNG FIBROSIS; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION; VASCULAR REMODELING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; HEART VENTRICLE REMODELING; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; FIBROSIS; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMIDAZOLES; LUNG; MALE; MONOCROTALINE; MYOCARDIUM; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PULMONARY FIBROSIS; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84926621346     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13044     Document Type: Article

References (61)

1. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, et al. (2003). Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 4: 27-30.
2. Adachi Y, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, et al. (2003). Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 107: 2406-2408.
3. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
5. Ali Q, Wu Y, Hussain T, (2013). Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int 84: 931-939.
6. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV, (2007). Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131: 1917-1928.
7. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, et al. (1997). Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 325 (Pt 2): 449-454.
8. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF, (2009). The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135: 794-804.
9. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE, (2011). Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 121: 297-303.
10. Bradley SP, Auger WR, Moser KM, Fedullo PF, Channick RN, Bloor CM, (1996). Right ventricular pathology in chronic pulmonary hypertension. Am J Cardiol 78: 584-587.
11. Budd DC, Holmes AM, (2012). Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther 135: 279-291.
12. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP, (2005). Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46: 937-942.
13. Cheever KH, (2005). An overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations, and management. J Cardiovasc Nurs 20: 16, quiz 117-118.
14. Chung WK, Deng L, Carroll JS, Mallory N, Diamond B, Rosenzweig EB, et al. (2009). Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant 28: 373-379.
15. Danyel LA, Schmerler P, Paulis L, Unger T, Steckelings UM, (2013). Impact of AT2-receptor stimulation on vascular biology, kidney function, and blood pressure. Integr Blood Press Control 6: 153-161.
16. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, et al. (2010). Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96: 287-294.
17. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T, (2000). International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472.
18. Gelosa P, Pignieri A, Fandriks L, de Gasparo M, Hallberg A, Banfi C, et al. (2009). Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 27: 2444-2451.
19. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. (2007). Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742.
20. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et al. (2009). Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54: S10-S19.
21. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. (1995). Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151: 1628-1631.
22. Hunyady L, Catt KJ, (2006). Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20: 953-970.
23. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436: 112-116.
24. Jiang XY, Gao GD, Du XJ, Zhou J, Wang XF, Lin YX, (2007). The signalling of AT2 and the influence on the collagen metabolism of AT2 receptor in adult rat cardiac fibroblasts. Acta Cardiol 62: 429-438.
25. Jing T, Wang H, Srivenugopal KS, He G, Liu J, Miao L, et al. (2009). Conditional expression of type 2 angiotensin II receptor in rat vascular smooth muscle cells reveals the interplay of the angiotensin system in matrix metalloproteinase 2 expression and vascular remodeling. Int J Mol Med 24: 103-110.
26. Kaschina E, Unger T, (2003). Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12: 70-88.
27. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, et al. (2008). Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532.
28. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
29. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. (2013). Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112: 1104-1111.
30. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, et al. (2005). Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19: 617-619.
31. Lipworth BJ, Dagg KD, (1994). Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. Chest 105: 1360-1364.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, et al. (2012). Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 780-789.
34. Morrell NW, Atochina EN, Morris KG, Danilov SM, Stenmark KR, (1995). Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 96: 1823-1833.
35. Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Iwai M, Horiuchi M, et al. (2006). Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem Biophys Res Commun 346: 658-664.
36. Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, Geurts N, et al. (2013). AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis 51: 177-191.
37. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW, (2000). Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 192: 379-384.
38. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
39. Qi Y, Shenoy V, Wong F, Li H, Afzal A, Mocco J, et al. (2011). Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol 96: 863-874.
40. Qi Y, Li H, Shenoy V, Li Q, Wong F, Zhang L, et al. (2012). Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. Exp Physiol 97: 89-101.
41. Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C, et al. (2010). Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55: 924-931.
42. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J, (2001). Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant 16 (Suppl. 1): 27-33.
43. Santos RA, Ferreira AJ, Verano-Braga T, Bader M, (2013). Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216: R1-R17.
44. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F, (2011). Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 8: 443-455.
45. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, et al. (2010). The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182: 1065-1072.
46. Shenoy V, Qi Y, Katovich MJ, Raizada MK, (2011). ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 11: 150-155.
47. Shenoy V, Gjymishka A, Jarajapu YP, Qi Y, Afzal A, Rigatto K, et al. (2013). Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med 187: 648-657.
48. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, et al. (2011). Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 11: 187-192.
49. Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, Steckelings UM, (2013). Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol 40: 580-588.
50. Tallant EA, Clark MA, (2003). Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579.
51. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M, (2010). Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 35: 1079-1087.
52. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, et al. (1998). Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 83: 1035-1046.
53. Villela D, Leonhardt J, Patel N, Joseph J, Kirsch S, Hallberg A, et al. (2015). Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci (Lond) 128: 227-234.
54. Viswanathan M, Saavedra JM, (1992). Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides 13: 783-786.
55. Wagenaar GT, el Laghmani H, Fidder M, Sengers RM, de Visser YP, de Vries L, et al. (2013). Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury. Am J Physiol Lung Cell Mol Physiol 305: L341-L351.
56. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, et al. (2004). Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47: 5995-6008.
57. Weber KT, Brilla CG, (1991). Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865.
58. Yamada T, Horiuchi M, Dzau VJ, (1996). Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 93: 156-160.
59. Yayama K, Hiyoshi H, Imazu D, Okamoto H, (2006). Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor. Hypertension 48: 958-964.
60. Zhao Y, Biermann T, Luther C, Unger T, Culman J, Gohlke P, (2003). Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. J Neurochem 85: 759-767.
61. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. (2003). Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108: 1707-1712.